NEW YORK (GenomeWeb News) – Cepheid's revenues grew 21 percent year over year during the second quarter, the Sunnyvale, Calif.-based firm reported after the close of the market on Thursday.

For the three months ended June 30, total revenues came in at $81.0 million, compared to $67.0 million a year ago. Wall Street analysts had expected revenues of $82.7 million.

Pacing revenue growth was reagent and disposable sales growth to $63.9 million from $49.5 million a year ago, a 29 percent increase. System sales increased 3 percent to $14.5 million from $14.1 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.